The Kappa‐Opiate Receptor Impacts the Pathophysiology and Behavior of Substance Use
Author:
- 8 July 2009
- journal article
- review article
- Published by Wiley in The American Journal on Addictions
- Vol. 18 (4) , 272-276
Abstract
There is increasing evidence that the kappa‐opiate receptor, in addition to the mu‐opiate receptor, plays an important role in substance use pathophysiology and behavior. As dopamine activity is upregulated through chronic substance use, kappa receptor activity, mediated through the peptide dynorphin, is upregulated in parallel. Dynorphin causes dysphoria and decreased locomotion, and the upregulation of its activity on the kappa receptor likely dampens the excitation caused by increased dopaminergic activity. This feedback mechanism may have significant clinical implications for treating drug dependent patients in various stages of their pathology.Keywords
This publication has 62 references indexed in Scilit:
- Dynorphin and the pathophysiology of drug addictionPharmacology & Therapeutics, 2007
- Stress-Induced p38 Mitogen-Activated Protein Kinase Activation Mediates κ-Opioid-Dependent DysphoriaJournal of Neuroscience, 2007
- Pharmacological Evidence for a Motivational Role of κ-Opioid Systems in Ethanol DependenceNeuropsychopharmacology, 2007
- κ-Opioid receptor modulation of accumbal dopamine concentration during operant ethanol self-administrationNeuropharmacology, 2006
- The many faces of CREBTrends in Neurosciences, 2005
- Possible Pharmacotherapy of the Opioid κ Receptor Agonist for Drug DependenceAnnals of the New York Academy of Sciences, 2004
- Antidepressant-Like Effects of κ-Opioid Receptor Antagonists in the Forced Swim Test in RatsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Effects of U-50,488H, a κ-opioid receptor agonist, on the learned helplessness model of depression in miceJournal of Neural Transmission, 2002
- Cocaine, Dopamine and the Endogenous Opioid SystemJournal of Addictive Diseases, 1996
- Dopamine antagonist and 'binge' cocaine effects on rat opioid and dopamine transporter mRNAsNeuroReport, 1996